Is Pulmatrix Inc (PULM) a Stock to Watch After Losing -4.11% This Week?

The market has been down on Pulmatrix Inc (PULM) stock recently. PULM gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Pulmatrix Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on PULM!

See Full PULM Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With PULM Stock Today?

Pulmatrix Inc (PULM) stock is trading at $2.80 as of 12:00 PM on Thursday, May 18, an increase of $0.13, or 4.87% from the previous closing price of $2.67. The stock has traded between $2.67 and $2.80 so far today. Volume today is less active than usual. So far 5,614 shares have traded compared to average volume of 17,841 shares. To see InvestorsObserver's Sentiment Score for Pulmatrix Inc click here.

More About Pulmatrix Inc

Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways. Click Here to get the full Stock Report for Pulmatrix Inc stock.